NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Valuation Check As GLP 1 Growth And Foundayo Approval Lift Guidance
Eli Lilly (LLY) has jumped back into the spotlight after its first quarter 2026 report, as strong GLP‑1 demand and fresh FDA approvals led management to lift full year revenue and profit guidance.
See our latest analysis for Eli Lilly.
The share price reaction around the earnings beat and guidance raise has been positive in the very near term, with a 1 day share price return of 3.07% and 7 day share price return of 8.98%. However, the 90 day share price return of 7.74% and year to date share...